Copyright
©The Author(s) 2016.
World J Transplant. Sep 24, 2016; 6(3): 599-607
Published online Sep 24, 2016. doi: 10.5500/wjt.v6.i3.599
Published online Sep 24, 2016. doi: 10.5500/wjt.v6.i3.599
All patients n = 313 (100%) | 20-yr survivors n = 157 (50%) | 20-yr non- survivors n = 141 (45%) | Ratio1 | Lost n = 15 (5%) | |
Virus-related cirrhosis | 92 (29.4%) | 46 (29.30%) | 39 (27.70%) | 1.18 | 7 |
Hepatitis B | 47 (15.0%) | 26 (16.6%) | 19 (13.5%) | ||
Hepatitis C | 32 (10.2%) | 13 (8.3%) | 17 (12.1%) | ||
Hepatitis B and D | 10 (3.2%) | 5 (3.2%) | 2 (1.4%) | ||
Hepatitis B and C | 3 (1.0%) | 2 (1.3%) | 1 (0.7%) | ||
Cholestatic/ autoimmune | 64 (20.4%) | 38 (24.2%) | 20 (14.2%) | 1.90 | 6 |
Alcoholic cirrhosis | 50 (16.0%) | 23 (14.6%) | 27 (19.1%) | 0.85 | |
Hepatobiliary malignancy | 36 (11.5%) | 7 (4.5%) | 28 (19.9%) | 0.25 | 1 |
HCC | 27 (8.6%) | 6 (3.8%) | 20 (14.2%) | ||
CCC | 5 (1.6%) | 0 (0.0%) | 5 (3.5%) | ||
Klatskin tumor | 4 (1.3%) | 1 (0.6%) | 3 (2.1%) | ||
Cryptogenic cirrhosis | 29 (9.3%) | 15 (9.6%) | 13 (9.2%) | 1.15 | 1 |
Acute liver failure | 23 (7.3%) | 16 (10.2%) | 7 (5.0%) | 2.29 | |
Others | 19 (6.1%) | 13 (8.3%) | 6 (4.3%) | 2.20 |
All patients n = 313 | 20-yr-survivors n = 157 | 20-yr-non-survivors n = 141 | P | |
Recipients | ||||
Age (yr) | 47 (14-66) | 44 (14-66) | 50 (25-65) | 0.001 |
Age < 18, n (%) | 2 (0.6) | 2 (1.3) | 0 (0) | 0.06 |
Age > 55, n (%) | 57 (18) | 19 (12) | 36 (26) | 0.03 |
Gender, n (%) female | 135 (43) | 77 (49) | 51 (36) | 0.03 |
labMELD-score | 18.6 (± 7.6) | 19.4 (± 8.3) | 18.1 (± 7.0) | 0.156 |
Urgent LT, n (%) | 23 (7) | 15 (10) | 8 (6) | 0.21 |
BMI (kg/m2) | 23.0 ± 3.3 | 22.7 ± 3.0 | 23.5 ± 3.7 | 0.037 |
HBMI, n (%) | 78 (25%) | 30 (19%) | 45 (32%) | 0.011 |
HLIP, n (%) | 45 (14%) | 20 (15%) | 23 (19%) | 0.376 |
Donors | ||||
Donor age (yr) | 30 (9-64) | 28 (14-64) | 33 (9-60) | 0.099 |
ET-DRI | 1.35 (± 0.2) | 1.32 (± 0.2) | 1.37 (± 0.2) | 0.121 |
Transplant | ||||
Cold ischemia time, h | 10.6 (± 4) | 10.6 (± 4) | 10.7 (± 4) | 0.994 |
Retransplantation, n (%) | 46 (15) | 18 (11) | 25 (18) | 0.120 |
Liver function | ||||
tBili | 8.1 ± 11.9 | 9.0 ± 12.6 | 7.7 ± 11.6 | 0.363 |
AST | 115 ± 460 | 124 ± 486 | 111 ± 454 | 0.820 |
ALT | 102 ± 233 | 102 ± 177 | 108 ± 286 | 0.849 |
INR | 1.76 ± 0.8 | 1.82 ± 0.8 | 1.7 ± 0.8 | 0.226 |
Clinical characteristics | ||||
Systolic BP (mmHg) | 120 ± 20 | 119 ± 20 | 122 ± 21 | 0.340 |
Diastolic BP (mmHg) | 71 ± 11 | 71 ± 12 | 72 ± 11 | 0.353 |
Laboratory parameters | ||||
Glucose (mg/dL) | 120 ± 58 | 116 ± 46 | 126 ± 70 | 0.174 |
Cholesterol (mg/dL) | 134 ± 72 | 129 ± 55 | 138 ± 86 | 0.311 |
Triglycerides (mg/dL) | 95 ± 67 | 91 ± 56 | 100 ± 80 | 0.326 |
Creatinine (mg/dL) | 1.0 ± 0.8 | 1.06 ± 1.0 | 0.95 ± 0.4 | 0.247 |
eGFR (mL/min per 1.73 m2) | 98 ± 59 | 106 ± 70 | 88 ± 39 | 0.007 |
20-yr survivors n = 155 | 20-yr non-survivors n = 140 | P | |
eGFR > 60 | 126 (80%) | 112 (79%) | 0.860 |
MIRF | 31 (20%) | 29 (21%) | 0.879 |
SIRF | 7 (4.5%) | 4 (2.9%) | 0.453 |
eGFR 30-39 | 10 (6.5%) | 5 (3.6%) | 0.261 |
eGFR 40-49 | 8 (5.2%) | 7 (5.0%) | 0.950 |
eGFR 50-59 | 8 (5.2%) | 13 (9.3%) | 0.169 |
eGFR 60-69 | 10 (6.5%) | 28 (20%) | 0.001 |
eGFR 70-79 | 10 (6.5%) | 22 (15.7%) | 0.011 |
eGFR 80-89 | 22 (14.2%) | 13 (9.3%) | 0.193 |
eGFR 90-99 | 16 (10.3%) | 14 (10.0%) | 0.927 |
eGFR 100-109 | 15 (9.7%) | 9 (6.4%) | 0.308 |
eGFR 110-119 | 10 (6.5%) | 7 (5.0%) | 0.593 |
eGFR > 120 | 47 (30.3%) | 28 (20.0%) | 0.042 |
- Citation: Buescher N, Seehofer D, Helbig M, Andreou A, Bahra M, Pascher A, Pratschke J, Schoening W. Evaluating twenty-years of follow-up after orthotopic liver transplantation, best practice for donor-recipient matching: What can we learn from the past era? World J Transplant 2016; 6(3): 599-607
- URL: https://www.wjgnet.com/2220-3230/full/v6/i3/599.htm
- DOI: https://dx.doi.org/10.5500/wjt.v6.i3.599